Decentralization in clinical trials is quickly turning into a must-have for companies that truly want to support patients, provide more convenience and reach recruitment goals. Decentralized clinical trials (DCTs) hold the potential to reach new, remote patient populations, innovate rare and orphan disease research, and accelerate medical discovery.
In order to conduct a DCT across multiple countries, you need to be aware of the current regulations on a local scale – which of the DCT components you’d like to include are allowed in your target countries.
This report contains information about DCT components and their status in the following 15 countries:
| Australia | France | Poland |
| Belgium | Germany | Russia |
| Brazil | Israel | South Korea |
| Canada | Italy | Spain |
| China | Japan | The UK |
We are a team of feasibility and patient recruitment experts within TrialHub – the most comprehensive clinical trial planning platform. TrialHub relies on state-of-the-art algorithms for collecting thousands of data sources and a network of local experts to provide a 360-degree overview of the clinical research landscape.
This report was generated thanks to our latest analysis of the country-specific documents regarding the use of decentralized trial components and reflects the international and local regulations and guidelines of 15 countries with latest update January 2022. All data sources are included in the report for your convenience.
If you’d like to know which DCT components are allowed in your target countries or would like the most up-to-date information about regulations, sites and patients, reach out to us – we can support you with data and insights.
If you would like more information about countries not included in the report or if you would like an update, reach out to our team.